Moleculin Biotech (NASDAQ:MBRX) CEO and Chairman Walter Klemp outlined the company’s near-term priorities and upcoming clinical catalysts during a corporate presentation, emphasizing progress in its Phase 3 program for Annamycin, a next-generation anthracycline being developed primarily for acute myeloid leukemia (AML). Company focus and management background Klemp described Moleculin as a “Phase 3 clinical stage […]